DeLiver Pharma ApS: Financial statements 2020
CVR: 39432714
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
DeLiver Pharma ApS (CVR 39432714) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -19,597 and a net result of DKK -113,852 compared with DKK -12,094 the year before. Equity in the 2020 report amounted to DKK 245,729. The solvency ratio was 96.5%.
- Gross Profit
- DKK -19,597
- Profit/Loss
- DKK -113,852
- Equity
- DKK 245,729
- Total Assets
- DKK 254,540
Official annual report
How creditworthy is DeLiver Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
DeLiver Pharma ApS has published its annual report for 2019. Revenue came to DKK 79,000, and the net result was DKK -12,094.
About DeLiver Pharma ApS
DeLiver Pharma ApS is a Danish company of the type Anpartsselskab based in Faaborg, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Niels Jonas Heilskov Graversen. The board consists of Jens Kristian Damsgaard (chair), Holger Jon Møller, Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. The company's owners include MOESTRUP HOLDING 2007 ApS, MØLLER HOLDING 2007 ApS and PHIDEAS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -20,487 and a net result of DKK -31,867 compared with DKK -21,682 the year before. Equity in the 2025 report amounted to DKK 163,221.